Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Rhea-AI Summary

Aspire Biopharma (NASDAQ:ASBP) announced the November 4, 2025 hire of Mark J. Jaroszeski, PhD to its scientific team. Dr. Jaroszeski is a tenured professor of Medical Engineering at the University of South Florida with a PhD in Engineering Science and a long record in DNA and drug delivery, including early in vivo electroporation work, 34 U.S. patents, and leadership roles in academic and startup research.

The company said his expertise will support development and optimization of Aspire's patent-pending sublingual delivery technology and help extend the platform across its pipeline of generic medicines.

News Market Reaction

+2.77%

3 alerts

+2.77% News Effect

+$311K Valuation Impact

$12M Market Cap

0.0x Rel. Volume

On the day this news was published, ASBP gained 2.77%, reflecting a moderate positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $311K to the company's valuation, bringing the market cap to $12M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

U.S. patents: 34 patents Licensed patents: 12 patents Licensees: 7 companies +5 more

8 metrics

U.S. patents 34 patents Held by Dr. Mark J. Jaroszeski

Licensed patents 12 patents Licensed to 7 companies from Dr. Jaroszeski’s portfolio

Licensees 7 companies Companies licensing Dr. Jaroszeski’s patents

Peer-reviewed articles 62 articles Publications by Dr. Jaroszeski

Books authored 2 books Authored by Dr. Jaroszeski

Book chapters 11 chapters Written by Dr. Jaroszeski

Conference presentations 114+ conferences Conferences where Dr. Jaroszeski presented

Journals reviewed 21 journals Journals for which Dr. Jaroszeski serves as reviewer

Market Reality Check

Price: $1.43 Vol: Volume 27,968,934 vs 20-d...

low vol

$1.43 Last Close

Volume Volume 27,968,934 vs 20-day avg 56,741,707 (relative volume 0.49), indicating activity below recent norms. low

Technical Shares at 0.1045 are trading below the 200-day MA of 0.41, reflecting a longer-term downtrend despite today’s gain.

Peers on Argus

ASBP gained 22.51% while the only peer in the momentum set, XCUR, showed a 4.12%...

1 Down

ASBP gained 22.51% while the only peer in the momentum set, XCUR, showed a 4.12% move down without news, suggesting today’s strength in ASBP was stock-specific rather than a sector-wide biotech move.

Historical Context

5 past events · Latest: Dec 04 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Business update	Positive	+2.5%	Q3 2025 update on clinical, regulatory, IP, and commercial progress.
Dec 02	Regulatory milestone	Positive	+1.1%	Pre-IND meeting request to FDA for sublingual aspirin program.
Nov 26	Key hire	Positive	+2.8%	Addition of Dr. Jaroszeski to support sublingual delivery platform.
Nov 06	Partnership outreach	Positive	-23.9%	Meetings with pharma partners at CPHI Frankfurt on aspirin program.
Oct 06	IP filing	Positive	+0.3%	Omnibus patent filing for rapid sublingual drug delivery platform.

Pattern Detected

Recent company news has generally been positive with mostly modest positive price reactions; one partnership/trade-show update drew a sharp negative move, indicating occasional divergence between upbeat headlines and trading.

Recent Company History

This announcement adds a high-profile scientific hire to a recent string of development and regulatory milestones. Since October 2025, ASBP has filed an omnibus patent application for its sublingual platform, highlighted partnership discussions at CPHI Frankfurt, submitted a Pre-IND package for its sublingual aspirin, and provided a Q3 2025 update emphasizing positive bioavailability data and a targeted H1 2026 NDA submission. The Jaroszeski hire on Nov 4, 2025 fits this pattern of building technical depth around the sublingual delivery platform.

Market Pulse Summary

This announcement adds a well-credentialed researcher to support Aspire’s patent-pending sublingual ...

Analysis

This announcement adds a well-credentialed researcher to support Aspire’s patent-pending sublingual delivery platform. Dr. Jaroszeski’s track record includes 34 U.S. patents, extensive DNA/drug delivery work, and participation in more than 100 clinical trials’ foundational research. In context, ASBP traded at 0.1045, far below its 9.86 52-week high, and below its 0.41 200-day MA. Investors following the story may watch how his expertise translates into pipeline progress, partnerships, and future regulatory milestones.

Key Terms

drug delivery technology, sublingual delivery, in vivo electroporation, chemotherapeutic agents, +4 more

8 terms

drug delivery technology medical

"a developer of a multi-faceted patent-pending drug delivery technology"

A drug delivery technology is any method or system that controls how a medicine is transported into the body, where it goes, and how fast it is released — think of it as the packaging and delivery route for a package so the contents arrive at the right address and time. Investors care because better delivery can make drugs more effective, safer, longer-lasting, and harder to copy, which can lower development risk, speed approvals, expand markets, and boost competitive value.

sublingual delivery medical

"advancing Aspire's proprietary sublingual delivery technology"

Sublingual delivery is a way to give a medicine by placing it under the tongue so it soaks through the mouth’s lining directly into the bloodstream, like placing a dissolving strip where it can be absorbed quickly. Investors care because this route can speed how fast a drug works, avoid breakdown in the stomach or liver, improve convenience and dosing, and influence patent value, regulatory hurdles, and commercial appeal.

in vivo electroporation medical

"He was one of the early pioneers performing in vivo electroporation"

In vivo electroporation is a technique that uses short electrical pulses applied to living tissue to temporarily open cell membranes so drugs, DNA, RNA or other therapeutic molecules can enter cells directly. For investors, it matters because this delivery method can improve the effectiveness and dosing of gene therapies, vaccines and local cancer treatments, affecting clinical success, regulatory risk and commercial potential much like a better delivery truck improves product reach and reliability.

chemotherapeutic agents medical

"protocols to deliver chemotherapeutic agents to tumors in animal models"

Drugs designed to kill, shrink or stop the spread of cancer cells, including traditional small-molecule medicines, targeted antibodies and other therapeutic compounds given by pill, injection or infusion. They matter to investors because clinical trial results, regulatory approvals, safety issues, manufacturing capacity and patent protection directly affect a company’s future sales, costs and legal risk—similar to how success or failure of a flagship product can make or break a business.

anti-tumor effects medical

"safely and effectively, with very strong anti-tumor effects"

Anti-tumor effects describe a treatment’s ability to slow, shrink or eliminate abnormal cell growth (tumors) in the body, either by killing tumor cells, stopping them from dividing, or cutting off their support systems. For investors, evidence of meaningful anti-tumor effects can signal a therapy’s potential clinical benefit, higher odds of regulatory approval, and significant commercial value—similar to how a weed killer that visibly clears a garden suggests the product works and could sell well.

clinical trials medical

"laid the foundation for more than 100 current clinical trials using gene delivery"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

manuscript reviewer technical

"He serves as a manuscript reviewer for 21 journals"

A manuscript reviewer is an expert who evaluates a scientific or technical paper before it is published, checking that the methods, data and conclusions are sound and clearly presented. Like a trusted editor or fact-checker, their approval increases confidence that the results are reliable, which matters to investors because strong, credible publications can influence regulatory decisions, clinical progress, company credibility and ultimately the market value of related firms.

International Bioelectrics Consortium medical

"delegate to the International Bioelectrics Consortium, a collection of research groups"

An international bioelectrics consortium is a formal collaboration of companies, research institutions and sometimes regulators focused on developing and applying technologies that use electric fields or pulses to influence biological tissues, such as for medical treatments, sterilization or lab research. For investors it signals pooled resources, shared risk and faster validation — like several neighbors funding a single road repair — which can speed product development, reduce costs and clarify regulatory pathways.

AI-generated analysis. Not financial advice.

ESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion.

"Dr. Jaroszeski is recognized globally for his pioneering work in DNA and drug delivery, and we are honored to welcome him to the Aspire team," said Kraig Higginson, Interim CEO of Aspire Biopharma. "He brings extensive experience in medical delivery systems that will be instrumental in advancing Aspire's proprietary sublingual delivery technology. His insight and track record of innovation will play a critical role as we continue to develop and optimize our platform, building on our initial pipeline and extending these benefits to a broader range of generic medicines."

Mark J. Jaroszeski, Ph.D., is Professor of Medical Engineering at the University of South Florida College of Engineering. Dr. Jaroszeski is a leading innovator in developing DNA/drug delivery technologies and methods to treat disease. He was one of the early pioneers performing in vivo electroporation during the early 1990's, and was among the first researchers to develop basic electrodes and pulsing protocols to deliver chemotherapeutic agents to tumors in animal models in vivo, safely and effectively, with very strong anti-tumor effects. His work on the frontiers of DNA/drug delivery over the past 20 years laid the foundation for more than 100 current clinical trials using gene delivery. He holds 34 U.S. patents, 12 of which have been licensed to 7 companies. He is also currently Vice President of Research for EF Therapeutics, Inc., a start-up company focused on DNA delivery and translating it to the human and veterinary clinical markets. He has published 62 articles in peer-reviewed journals, two books and 11 book chapters, and presented at more than 114 conferences worldwide. He serves as a manuscript reviewer for 21 journals, as well as frequent reviewer for the National Institutes of Health. He has organized/chaired seven professional conferences, and is a delegate to the International Bioelectrics Consortium, a collection of research groups from about 15 countries.

About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.
Contact
Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

FAQ

Who did Aspire Biopharma (ASBP) hire on November 4, 2025?

Mark J. Jaroszeski, PhD, a tenured professor of Medical Engineering at the University of South Florida, joined Aspire's scientific team on November 4, 2025.

What expertise does Dr. Mark Jaroszeski bring to ASBP?

He brings expertise in DNA and drug delivery, early in vivo electroporation research, 34 U.S. patents, and experience translating delivery technologies to clinical markets.

How will the Dr. Jaroszeski hire affect Aspire's sublingual delivery program (ASBP)?

The company said his experience will support development and optimization of Aspire's patent-pending sublingual delivery technology and help extend it across the company's pipeline.

Does Dr. Jaroszeski have commercial or startup experience relevant to ASBP?

Yes; he serves as Vice President of Research for EF Therapeutics, a startup focused on DNA delivery, and has 12 patents licensed to seven companies.

What academic and publication credentials does Dr. Jaroszeski hold relevant to ASBP investors?

He has published 62 peer-reviewed articles, two books, 11 book chapters, presented at over 114 conferences, and reviews for 21 journals and NIH.